Trials / Recruiting
RecruitingNCT07483307
A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer
Impact of Neoadjuvant Endocrine Therapy on Surgical Outcomes in Patients With Stage 2 to 3 Invasive Lobular Carcinoma: A Prospective Study
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 176 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- Female
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to look at how effective neoadjuvant (before surgery) endocrine therapy (NET) is in participants with invasive lobular carcinoma (ILC) who have breast-conserving surgery (BCS). The main purpose of the study is to see if NET reduces the chance of having cancer cells at the edges of tissue removed during surgery (positive margins).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Neoadjuvant endocrine therapy | The endocrine therapy used for the NET in this study will be anastrozole, letrozole, exemestane, or tamoxifen. |
Timeline
- Start date
- 2026-03-13
- Primary completion
- 2030-03-13
- Completion
- 2030-03-13
- First posted
- 2026-03-19
- Last updated
- 2026-03-19
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07483307. Inclusion in this directory is not an endorsement.